Genmab — Juli 2018
-
Fredag den 13, vi har fortjent en fredagsnyhed, det er længe siden, vi har haft en
-
i går var torsdag, jeg efterlyste en fredags nyhed
-
Hvor de skrev: 2our findings demonstrate the adaptability of the ACTR platform to function in combination with daratumumab, and bypass the challenges of scFv-based CAR-T cell production to safely and effectively target CD38-positive multiple myeloma"
-
the anti-myeloma activity of ACTR T cells in combination with daratumumab. ACTR T cells mediated robust cytotoxicity, cytokine production, and proliferation in response to a range of daratumumab-opsonized target cell lines. Notably, the target specific killing and cytokine production mediated by ACTR T cells in combination with daratumumab was greater than the activity mediated by daratumumab alone.
-
-
Tak Peter12. Det er kun et spørgsmål om tid inden NICE. og J&J bliver enige om prisen. At det bliver second Line er ikke så relevant i første ombæring . Når det bliver godkendt i first line i EU kommer NICE også med , da det sikkert bliver et krav fra div. Patientforeninger . Lad os nu håbe og tro på gode MAIA resultater og gode JNJ Q 2 tal
-
F.eks. 20% i et par år. Derefter kan NICE lave en cost benefit analyse på besparelsen ved at bruge det bedste præparat i stedet for det næstbedste.
-
Problemet for J&J er nok, at rabatter til enkelte lande får andre til at kræve det samme.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind